ClinicalTrials.gg
TerminatedNCT05394857Updated Dec 27, 2024

Efficacy and Safety of SHR-1314 by Subcutaneous Injection in Active Moderate to Severe Graves' Orbitopathy Patients

A Phase 2 interventional study of SHR-1314 in Active Moderate to Severe Graves' Orbitopathy, sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. Terminated at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-12-27.

Sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

Why this study was terminated
Sponsor commercial considerations

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies in Graves Ophthalmopathy with a site in China — 25 open to participants now, 28 under way, 7 of them phase 3. Graves Ophthalmopathy · China.

Enrollment
44th of 45
7 · median 64
Started
2022
with 3 others
Phase 2
6 of 55
2 open now
Registered
16th of 55
by date

Among the 55 studies in Graves Ophthalmopathy with a site in China, this one is the 44th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 2, and was the 16th registered.

Graves Ophthalmopathy

199 studies on the registry are indexed under Graves Ophthalmopathy; 58 are open to participants now.

Browse Graves Ophthalmopathy studies →

Open to participants now

25 of the 55 studies in Graves Ophthalmopathy with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 38 Graves Ophthalmopathy studies recruiting now, 8 (21%) set no upper age limit and 16 (42%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Graves Ophthalmopathy with a site in China, or all of them as a file.
02

Study summary

This is a single-arm, prospective, open-label, Phase II study that explored the efficacy and safety of SHR-1314 in active moderate to severe Graves' Orbitopathy. The study consists of a 6-week screening period, a 16-week treatment period, and a 12-week follow-up period. Eighteen adult patients with active moderate to severe Graves' Orbitopathy will be enrolled. Eligible subjects will receive SHR-1314 subcutaneously. The primary endpoint was the proptosis responder rate and will be evaluated at 16weeks.

03

Conditions studied

  • Active Moderate to Severe Graves' Orbitopathy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated before any study assessment is performed.
  2. Male or female between the ages of 18 and 70 (including boundary values)
  3. Onset of active GO symptoms fewer than 9 months prior to baseline.
  4. Clinical diagnosis of Graves' disease associated with active GO with a CAS ≥ 3 (on the 7-item scale) for the most severely affected eye(study eye) at Screening and Baseline.
  5. Moderate-to-severe active GO (not sight-threatening but has an appreciable impact on daily life).
  6. Does not require immediate surgical ophthalmological intervention.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women.
  2. allergy to the study drug or to any component of the study drug.
  3. Significant abnormalities in laboratory and .
  4. Decreased best corrected visual acuity due to optic neuropathy as defined by a decrease in vision of 2 lines on the Snellen chart, new visual field defect, or color defect secondary to optic nerve involvement within the last 6 months.
  5. Corneal decompensation unresponsive to medical management.
  6. Decrease in CAS of ≥ 2 points between Screening and Baseline.
  7. Decrease in proptosis of ≥ 2 mm between Screening and Baseline.
  8. Previous orbital irradiation or surgery for TED.
  9. Any other ophthalmic disease that might interfere the study or the study result confirmed by investigator.
  10. Patients with serious, progressive and uncontrolled cardiovascular, liver, kidney, lung, gastrointestinal, hematopoietic, endocrine, nervous and psychiatric diseases, or other conditions that considered inappropriate for patients to participate this study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Treatment group

    SHR-1314 s.c

    Drug: SHR-1314

Interventions

06

What researchers measure

Primary outcomes

  1. the proptosis responder rate

    Proptosis responder is defined as a ≥ 2 mm reduction from Baseline in proptosis in the study eye, without deterioration \[≥ 2 mm increase\] of proptosis in the fellow eye)

    Time frame: week 16

Secondary outcomes

  1. Proportion of patients achieving response in reduction of clinical activity score(CAS)

    reduction of CAS is defined as reduction of ≥ 2 points of CAS from Baseline to Week16.

    Time frame: week 16

  2. Overall responder rate

    Overall responder rate is defined as percentage of subjects with≥ 2-point reduction in CAS AND ≥ 2 mm reduction in proptosis from Baseline, provided there is no corresponding deterioration \[≥ 2-point/mm increase\] in CAS or proptosis in the fellow eye at Week 16

    Time frame: week 16

  3. The percentage of subjects with a CAS value of 0 or 1 in the study eye

    the clinical activity score of subject is 0 or 1.

    Time frame: week 16

  4. The mean change from Baseline to Week 16 in proptosis measurement in the study eye

    Average change in proptosis in study eye.

    Time frame: week 16

  5. Diplopia response rate at Week16

    Proportion of participants with Baseline diplopia \> 0 and a reduction of ≥ 1 grade with no corresponding deterioration (≥ 1 grade worsening) in the fellow eye at Week 16.

    Time frame: week 16

  6. The mean change from Baseline to Week 16 in the GO-QoL score

    Average change in the Graves' ophthalmopathy quality of life questionnaire (GO-QOL) score. The GO-QoL contains 8 questions on visual functioning and 8 questions on appearance; answers on each subscale are transformed to scores ranging from 0 (worst) to 100 (best).

    Time frame: week 16

07

Study locations

1 site
  • Shanghai Ninth People's Hospital,Shanghai Jiao Tong University School of Medical
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2022 to primary completion in Aug 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2022
First posted
May 27, 2022
StartActual
Sep 13, 2022
Primary completionActual
Aug 22, 2023
CompletionActual
Aug 22, 2023
Last update
Dec 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05394857
Responsible party
Sponsor
First posted
May 27, 2022
Start date
Sep 13, 2022
Primary completion
Aug 22, 2023
Completion
Aug 22, 2023
Last update
Dec 27, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vunakizumab

Start the discussion